Global Central Nervous System Therapeutics Market Size By Disease (Neurovascular Diseases, Trauma, Mental Health), By Drug Class (Analgesics, Nervous System Drugs, Anesthetics), By Geographic Scope And Forecast

Central Nervous System Therapeutics Market Size And Forecast

Central Nervous System Therapeutics Market size was valued at USD 85.24 Billion in 2021 and is projected to reach USD 170.43 Billion by 2030, growing at a CAGR of 9.45% from 2023 to 2030.

The structure and function of the brain and spinal cord are being affected by an increase in CNS disorders such as neurodegenerative diseases, autoimmune and inflammatory diseases, genetic disorders, malignancies, and others. To treat these problems, CNS medications are required. The Global Central Nervous System Therapeutics Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Central Nervous System Therapeutics Market Definition

The central nervous system (CNS), made up of the brain and spinal cord, is super important! Think of it as the body's command center – it takes in all sorts of information, then figures out what to do and tells everything else how to work. Unfortunately, neurovascular problems, like brain aneurysms, arteriovenous malformations (AVMs), carotid artery disease, and intracranial atherosclerotic disease, can really mess things up. These conditions have a big impact on health and cost a lot of money in the US. They can lead to serious neurological problems like stroke, subarachnoid hemorrhage, disability, and even death. The Brain Aneurysm Foundation says that around 6 million Americans have cerebral aneurysms, and these cause about half a million deaths worldwide each year. What's even scarier is that half of the people affected are under 50.

Any operation that necessitates the use of an operating microscope is referred to as microsurgery. Traditional open surgery with very small equipment and a microscope can be used to treat neurovascular disorders (microsurgery).To avoid difficulties, this sort of surgery entails working around very small, sensitive nerves and brain parts that must be treated gently and carefully. Aneurysm clipping, skull base surgery, and neurovascular surgery are all examples of microsurgery. To obtain the best possible results, neurosurgeons combine the latest microsurgery techniques with computer-guided localization and comprehensive intraoperative monitoring.

Imagine blood vessels that need a little help. Endovascular surgery is like having a tiny repair crew go inside those vessels, like when a blood vessel has a bulge or balloon – that's called an aneurysm. They use a catheter, a thin tube, that goes in through a small cut in the groin and then it is guided right to where it is needed, say the brain. The cool thing is, it's way less intense than traditional surgery – less pain, shorter hospital stays, and fewer risks! Think of procedures like coiling, stenting, angioplasty, and embolization, those are all examples of this type of surgery. Now, on a different note, degenerative disc disease isn't a disease itself, but rather a group of symptoms you might get if your spinal discs wear down over time, or from a sudden injury.

Global Central Nervous System Therapeutics Market Overview

The Central Nervous System (CNS) Therapeutics Market is really taking off, and it's all thanks to some amazing progress! Think better diagnostics, newer treatments, and faster ways to discover new drugs. Plus, there's a huge need for better CNS therapies, which is pushing the big pharma companies to invest heavily in research and development. On top of all that, we're seeing more awareness about mental health, and unfortunately, more people are experiencing mental illness and CNS disorders related to how we live our lives. An aging population also plays a part! What's really concerning is that we've seen a rise in psychological distress among teenagers and young adults in recent years, and that's also driving the demand for CNS therapies globally.

It's a bit of a tough spot for the Central Nervous System Therapeutics Market, though. Strict drug approval processes and rising costs for new treatments could really slow things down. On the other hand, the WHO says that 50 million people globally are dealing with dementia, and a whopping 60% of those folks are in countries with fewer resources. And, according to the Parkinson’s Foundation, we're talking about 2.8 million people with multiple sclerosis and ten million with Parkinson's worldwide. Finding good treatment options for these disorders can be a real challenge. Right now, there are just five approved drugs for Alzheimer's, but hey, there's some good news! There are currently 146 clinical studies in Phases 1, 2, and 3 actively looking for participants, which could mean more options down the line.

Agents capsules for Parkinson’s disease when a patient’s meds aren’t functioning and Zeposia capsules for relapsing types of multiple sclerosis were recently approved by the FDA. According to Alzheimer’s Europe, the European Union’s dementia population is expected to be at 7.8 million people. Furthermore, the Harvard NeuroDiscovery Center predicts that almost 12 million Americans will be affected by neurodegenerative disorders in 30 years if no action is taken. As a result of the rising prevalence of these diseases, the medication development pipeline, and the potential of this segment, clinical trials, product launches, and strategic alliances are becoming more common.

Did you know that back in 2010, the National Institute on Aging tells us there were already a whopping 524 million people over 65? That's about 8% of everyone on the planet! And get thisby 2050, they're expecting that number to jump to 1.5 billion, making up more than 16% of the world's population. As we get older, brain issues, sadly, become more common. That's why governments and non-profits are doing lots of things worldwide to help people understand illnesses affecting the CNS. They're also raising money to boost clinical research and hopefully come up with better ways to treat these diseases. For instance, every year on April 11th, we mark World Parkinson’s Day.

Global Central Nervous System Therapeutics MarketSegmentation Analysis

The Global Central Nervous System Therapeutics Market is segmented on the basis of Disease, Drug Class, And Geography.

Central Nervous System Therapeutics Market, By Disease

• Neurovascular Diseases
• Trauma
• Mental Health
• Degenerative Diseases
• Infectious Diseases
• Cancer
• Other Infectious Diseases

So, the market, based on what ails us, is broken down into categories like Neurovascular Diseases, Trauma, Mental Health, Degenerative Diseases, Infectious Diseases, Cancer, and even Other Infectious Diseases. Now, when we talk about neurovascular disease, we're really talking about anything that goes wrong with the blood vessels in and around your brain and spine. This could be something like your arteries getting too narrow, which chokes off blood flow and ups your chances of a stroke – especially the "ischemic" kind. Or, it could be weakness in those arteries, leading to scary things like brain aneurysms and bleeding inside your skull, or a hemorrhagic stroke. Often, if someone's had a stroke, they'll suddenly feel weak or numb on one side. They might also have trouble speaking or seeing, and their balance could be all off. Sometimes, though, folks just get a heads-up with minor symptoms that vanish as quickly as they came.

Central Nervous System Therapeutics Market, By Drug Class

• Analgesics
• Nervous System Drugs
• Anesthetics
• Anti-Parkinson Drugs
• Anti-Epileptics
• Other Drug Classes

Based on Drug Class, The market is divided into Analgesics, Nervous System Drugs, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Other Drug Classes. The peripheral and central nervous systems are both affected by Analgesic Medications. An Analgesic that reduces pain. This is particularly true with pain relievers like acetaminophen. Analgesics include medications classed as NSAIDs (nonsteroidal anti-inflammatory drugs), such as ibuprofen. Opioid and opiate compounds, as well as non-opioid pharmaceuticals, are Analgesics. They can be prescribed or purchased over the counter. For a desired therapeutic effect, several nonopioid and nonopioid-opioid formulations also operate as antipyretics and anti-inflammatory drugs.

Central Nervous System Therapeutics Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, The Global Central Nervous System Therapeutics Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Asia Pacific region is expected to witness a significant CAGR during the forecast period. This is primarily due to the structure and function of the brain and spinal cord are being affected by an increase in CNS disorders such as neurodegenerative diseases, autoimmune and inflammatory diseases, genetic disorders, malignancies, and others. To treat these problems, CNS medications are required.

Key Players

The “Global Central Nervous System Therapeutics Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Biogen Inc, Otsuka Pharmaceutical Co. Ltd, Eli Lilly and Company, Merck KGaA, AstraZeneca, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Private Limited, GlaxoSmithKline PLC.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• April 2021, The National Medical Products Administration (NMPA) has approved Biogen’s TECFIDERA (dimethyl fumarate) to treat relapsed multiple sclerosis, allowing the company to extend its presence in China.
• April 2021, Patients are still being recruited for phase III clinical studies of aripiprazole to treat Alzheimer’s dementia, according to Otsuka and Lundbeck.
• June 2021, GSK and iTeos Therapeutics have announced an agreement to develop and commercialize EOS-448, an anti-TIGIT monoclonal antibody that will enable novel next-generation immuno-oncology combinations.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

We dive deep into the market, looking at it from all angles, both the money side and the human side with segmentation. You'll get hard numbers—the market value (in USD Billion) for every piece of the pie. We'll point out which region and segment are set to explode and which will be the top dog. Plus, we break down each region, showing where the product is being used and what's driving the market there. We'll map out the competitive landscape, ranking the big players and highlighting their latest moves—new products, partnerships, expansions, and acquisitions from the last five years. Expect detailed company profiles covering everything from company overviews and insights to product comparisons and SWOT analyses. You'll also get our take on where the market's headed, based on recent happenings, growth potential, and the hurdles ahead in both up-and-coming and established regions. We even dig into the market's inner workings with Porter's five forces and a look at the value chain. Finally, we'll lay out the market dynamics, spotlighting growth opportunities down the road and offer 6-month post-sales analyst support.

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.